Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Jan
11
2021
Medi-Cal Rx: California to Transition Medi-Cal Pharmacy Benefits to Fee-For-Service Sheppard, Mullin, Richter & Hampton LLP
Feb
18
2021
Recent FTC Settlement Serves as Reminder For Digital Health Developers Sheppard, Mullin, Richter & Hampton LLP
Sep
30
2009
OTC Drug and Dietary Supplement Labeling: Adverse Event Reporting Information Sheppard, Mullin, Richter & Hampton LLP
Sep
22
2021
Elijah E. Cummins Lower Drug Costs Now Act: The Long and Winding Road to Drug Pricing Reform Sheppard, Mullin, Richter & Hampton LLP
Jul
19
2018
340B Drug Pricing Program Litigation Update: American Hospital Association, Et Al. v. Azar Sheppard, Mullin, Richter & Hampton LLP
Nov
22
2021
FDA Joins Other Regulators in Focus on AI and Machine Learning Sheppard, Mullin, Richter & Hampton LLP
Mar
24
2022
HHS OIG Signs Off on Substance Use Recovery Incentive Program Sheppard, Mullin, Richter & Hampton LLP
Apr
18
2014
Review – U.S. Patent and Trademark Office Subject Matter Eligibility Guidelines Sheppard, Mullin, Richter & Hampton LLP
Dec
5
2014
Now That That’s Settled: The Status of Class Action Settlements in the Seventh Circuit after Pella, Radioshack and NBTY Sheppard, Mullin, Richter & Hampton LLP
Sep
15
2022
California Expands FEHA to Include Off The Job Cannabis Use Sheppard, Mullin, Richter & Hampton LLP
Oct
31
2022
CMS Heightens Oversight of TPMO Marketing Programs, Restricts TV Advertisements Sheppard, Mullin, Richter & Hampton LLP
Mar
17
2015
California Federal Court Finds that Class Action Plaintiffs’ False Advertising Claims are Stripped Bayer Based on Federal Preemption Sheppard, Mullin, Richter & Hampton LLP
Dec
6
2022
Don’t Let Drugs Bring You Down: The Importance of an Effective Drug Diversion Program Sheppard, Mullin, Richter & Hampton LLP
Aug
28
2015
What’s in a Name? That Which We Call a Biological Product… Sheppard, Mullin, Richter & Hampton LLP
Apr
24
2023
On the Horizon: Broad Employment Protections for Marijuana Users in the District of Columbia Sheppard, Mullin, Richter & Hampton LLP
Jun
16
2023
FDA Issues First Untitled Letter of the Year to Xeris Pharmaceuticals Sheppard, Mullin, Richter & Hampton LLP
Jul
12
2023
Commercial Cannabis Permit Program and Overlay District Statutorily Exempt Under CEQA Guideline Section 15183 Sheppard, Mullin, Richter & Hampton LLP
Sep
27
2023
Overview of Recent Anti-Corruption Enforcement Actions in the Pharmaceutical Industry in China Sheppard, Mullin, Richter & Hampton LLP
Apr
21
2020
Telehealth and Online Prescribing: COVID-19 Triggers Changes to the Prescriber/Patient/Pharmacist Relationship Sheppard, Mullin, Richter & Hampton LLP
Oct
14
2016
Proposed New FDA Labeling Rules Would Result in Increased Generic Drug Product Liability Claims Sheppard, Mullin, Richter & Hampton LLP
Aug
19
2020
President Trump’s Executive Order Mandating the Purchase of U.S. Drugs Evokes Criticism Sheppard, Mullin, Richter & Hampton LLP
Oct
2
2020
FDA’s Proposed Rule on “Intended Use” Confirms Agency Will Rely on “Any Relevant Source” of Evidence Sheppard, Mullin, Richter & Hampton LLP
Dec
4
2020
Cannabis Gets Go-Ahead from House, But Still Faces Hurdles Before Federal Legalization Sheppard, Mullin, Richter & Hampton LLP
Jul
10
2017
Giving Telemedicine More Room to Breathe: Recent and Pending State and Federal Actions in the World of Online Prescribing Sheppard, Mullin, Richter & Hampton LLP
Oct
3
2013
The Food and Drug Administration (FDA) Releases Long-Awaited Final Guidance on Mobile Medical Applications Sheppard, Mullin, Richter & Hampton LLP
Jun
3
2014
Northern District of California Courts Still Searching for Sweet Spot in “Evaporated Cane Juice” Cases: Confusion Over Applicability of Primary Jurisdiction to ECJ Claims Continues Sheppard, Mullin, Richter & Hampton LLP
May
11
2022
Warning! FDA Issues Warning Letters for Products Containing Delta-8 THC Sheppard, Mullin, Richter & Hampton LLP
Jun
27
2022
Supreme Court Rules for Physicians in Blow to DOJ Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins